456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors. - Postel-Vinay, S.; Italiano, A.; Martin Romano, P.; Cassier, P.A.; Siu, L.L.; Lossos, I.S.; Hilton, J.F.; Mckean, M.A.; Strauss, J.; Falchook, G.S.; de Jonge, M.J.A.; Opdam, F.L.; et al. (Annals of Oncology, 2022)